 Ferenc Tracik, MD to deliver presentation - From Monotherapy to Combination Therapy: Considering a Paradigm Shift to Target Complexity of ALS Phase IIb ALS study for NeuroSenses combination therapy PrimeC expected to commence Q2 2022 CAMBRIDGE, Mass. , May 23, 2022 PRNewswire -- NeuroSense Therapeutics Ltd. 